LeMaitre Vascular, Inc. $LMAT Shares Sold by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. has reduced its holdings in LeMaitre Vascular by 54.3%, owning approximately 73,836 shares valued at $6.19 million after selling 87,872 shares in the first quarter.
• LeMaitre Vascular reported a quarterly EPS of $0.60, which exceeded estimates and reflects a 15% year-over-year revenue increase to $63.15 million.
• The company declared a quarterly dividend of $0.20 per share, resulting in an annualized yield of 0.8%, with a payout ratio of 38.83%.

Raymond James Financial Inc. trimmed its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 54.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 73,836 shares of the medical instruments supplier's stock after selling 87,872 shares during the quarter. Raymond James Financial Inc. owned approximately 0.33% of LeMaitre Vascular worth $6,195,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of LMAT. Opal Wealth Advisors LLC purchased a new position in shares of LeMaitre Vascular in the first quarter worth $26,000. NBC Securities Inc. bought a new position in shares of LeMaitre Vascular in the first quarter worth about $36,000. US Bancorp DE lifted its position in shares of LeMaitre Vascular by 36.0% in the 1st quarter. US Bancorp DE now owns 1,390 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 368 shares during the period. Cetera Investment Advisers lifted its position in shares of LeMaitre Vascular by 11.5% during the fourth quarter. Cetera Investment Advisers now owns 2,753 shares of the medical instruments supplier's stock valued at $254,000 after buying an additional 284 shares during the last quarter. Finally, Blueshift Asset Management LLC purchased a new stake in shares of LeMaitre Vascular during the first quarter valued at about $232,000. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In related news, Director David B. Roberts sold 10,815 shares of LeMaitre Vascular stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the transaction, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This trade represents a 37.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of LeMaitre Vascular stock in a transaction on Friday, August 8th. The shares were sold at an average price of $94.00, for a total transaction of $235,000.00. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at approximately $274,104. This trade represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Stock Up 0.4%

NASDAQ:LMAT traded up $0.42 during mid-day trading on Friday, hitting $97.49. The stock had a trading volume of 140,809 shares, compared to its average volume of 183,915. The stock has a 50-day simple moving average of $88.64 and a two-hundred day simple moving average of $86.20. The company has a market capitalization of $2.21 billion, a PE ratio of 47.33, a PEG ratio of 2.50 and a beta of 0.79. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million for the quarter, compared to analysts' expectations of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The firm's revenue was up 15.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular's dividend payout ratio is currently 38.83%.

Analyst Upgrades and Downgrades

Several analysts have commented on LMAT shares. Barrington Research upgraded shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald boosted their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $97.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.